(Q29938509)

English

ABL1 BCR::ABL M244V

genetic variant

M244V
RS121913456
M263V
MET244VAL
MET263VAL
BCR-ABL M244V
BCR-ABL MET244VAL
BCR-ABL1 M244V
BCR-ABL1 MET244VAL
BCR::ABL M244V

In more languages

default for all languages

No label defined

No description defined

Statements

missense mutation

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

transcript fusion

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

human chromosome 9

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

133738330

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

133738330

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

biological variant of

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

positive therapeutic predictor for

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2638

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

negative therapeutic predictor for

dasatinib monohydrate

determination method or standard

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4302

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4307

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

imatinib mesylate

determination method or standard

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/6242

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4308

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

imatinib mesylate

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/6994

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

imatinib mesylate

determination method or standard

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/7042

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

determination method or standard

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/7771

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

determination method or standard

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/7825

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

dasatinib monohydrate

determination method or standard

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4304

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

determination method or standard

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2636

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

dasatinib monohydrate

determination method or standard

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4305

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

statement disputed by

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2640

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

dasatinib monohydrate

determination method or standard

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

statement disputed by

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2640

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines

Identifiers

CIViC variant ID

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_005157.5:c.730A>G

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

NP_005148.2:p.Met244Val

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

NC_000009.11:g.133738330A>G

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

ENST00000318560.5:c.730A>G

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1021

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29938509&oldid=2014804796"